ArticleMolecular cancer2017

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.

Francesca Ricci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.